Y Intercept Hong Kong Ltd Has $5.98 Million Stock Holdings in Teleflex Incorporated $TFX

Y Intercept Hong Kong Ltd boosted its stake in Teleflex Incorporated (NYSE:TFX) by 16.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 50,541 shares of the medical technology company’s stock after buying an additional 7,038 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Teleflex were worth $5,982,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of TFX. Thurston Springer Miller Herd & Titak Inc. grew its stake in Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock valued at $26,000 after buying an additional 153 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in Teleflex in the 1st quarter valued at about $27,000. Costello Asset Management INC bought a new stake in Teleflex in the 1st quarter valued at about $28,000. Brooklyn Investment Group boosted its holdings in Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 150 shares during the period. Finally, Allworth Financial LP boosted its holdings in Teleflex by 504.8% in the 1st quarter. Allworth Financial LP now owns 254 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 212 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Price Performance

Shares of NYSE TFX opened at $132.62 on Tuesday. Teleflex Incorporated has a twelve month low of $108.90 and a twelve month high of $239.13. The firm has a fifty day simple moving average of $126.53 and a 200 day simple moving average of $123.56. The company has a market capitalization of $5.86 billion, a PE ratio of 31.21, a P/E/G ratio of 1.84 and a beta of 1.05. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.36 by $0.37. The business had revenue of $780.90 million during the quarter, compared to analysts’ expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $3.42 earnings per share. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, sell-side analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, August 15th. Teleflex’s dividend payout ratio (DPR) is presently 32.00%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TFX shares. Wall Street Zen downgraded shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Wells Fargo & Company cut their price target on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a report on Friday, August 1st. Royal Bank Of Canada upped their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a report on Wednesday, October 8th. Finally, Mizuho upped their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $141.57.

Insider Activity at Teleflex

In other news, CEO Liam Kelly purchased 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average cost of $115.07 per share, with a total value of $172,605.00. Following the completion of the transaction, the chief executive officer directly owned 45,267 shares of the company’s stock, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Stuart A. Randle acquired 1,000 shares of the stock in a transaction on Tuesday, August 5th. The stock was bought at an average cost of $115.86 per share, for a total transaction of $115,860.00. Following the transaction, the director owned 7,547 shares of the company’s stock, valued at approximately $874,395.42. This trade represents a 15.27% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 5,500 shares of company stock valued at $633,590 over the last three months. Insiders own 1.40% of the company’s stock.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.